Novavax, Inc. (NVAX) — closed signal from January 26, 2026
Near target Published before the outcome was known, scored automatically when the window closed on April 26, 2026 — -17% at the close.
Predicted vs. what happened
What happened
Came within reach: 84% of the predicted growth at its peak, just short of the target.
The thesis — published January 26, 2026
Pfizer agreed to use Novavax's Matrix-M ingredient, which gives Novavax immediate cash and the chance to earn more from future payments. That deal changed what investors expect, so the stock moved up quickly. Because headlines can change recommendations for vaccines and move the price suddenly, it is safer to look for price pullbacks to get a better deal.
Primary drivers
- Pfizer deal gives cash now and possible future payments
- Deal can make the stock trade in a new, higher range
- Changes in vaccine policy can suddenly lower demand
- Big daily trading fits short-term positions and profit-taking
How it played out
NVAX: target was not reached
Lyra published NVAX at 9.90 on 2026-01-26 with a short-term thesis for 25% expected growth. The thesis pointed to Pfizer using Novavax's Matrix-M ingredient, immediate cash, possible future payments, a higher trading range, vaccine policy risk, and big daily trading that fit short-term positions and profit-taking.
Inside the window, NVAX rose to 11.97 on 2026-02-26, a 20.9% peak gain. That stayed below the 12.38 target. The target was never reached. By 2026-04-26, the stock ended at 8.22. The thesis partly played out on the early move, but it missed the published target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.